BioSpace News Archive

According to the report, the global chemiluminescence immunoassay (CLIA) analyzers market was valued at US$ 5.04 Bn in 2022 and is anticipated to expand at a CAGR of 6.3% from 2022 to 2030.

According to the report, the global genetic testing services market was valued at US$ 41.2 Bn in 2022 and is anticipated to expand at a CAGR of 7.3% from 2022 to 2030.

Frontier Biotechnologies, announced positive results from the Phase 1 clinical trial of its drug candidate, FB2001 – a small molecule inhibitor of coronavirus main protease (Mpro) – in healthy adult volunteers.

The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors.

Amgen (NASDAQ: AMGN) today announced new data from the DeLLphi300 clinical trial, a Phase 1 dose exploration and expansion study evaluating the safety and efficacy of investigational tarlatamab, a potential first-in-class half-life extended bispecific T-cell engager (HLE BiTE®) molecule targeting delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, reported financial and operating results for the second quarter and first half of 2022.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, reported financial results for the second quarter ended June 30, 2022 and provided clinical development and operational highlights.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the second quarter ending June 30, 2022.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.